February 14, 2013
A recent study explores challenges faced by pharmaceutical companies in their interactions with regulatory agencies
A recent study explores challenges faced by pharmaceutical companies in their interactions with regulatory agencies
RESEARCH TRIANGLE PARK, N.C.--()--Half of all drug companies
surveyed by Cutting Edge Information said that their regulatory affairs team interacts with correspondents in the
FDA once a week or more.
Of the remaining corporations who interact with them less frequently, 23% still speak with the FDA at least once a month. Most regulatory affairs groups recognize the importance of keeping frequent contact with regulatory agencies, and doing so build better relationships that help drug companies better prepare submission packages for regulatory approval.
Continue Reading here
Of the remaining corporations who interact with them less frequently, 23% still speak with the FDA at least once a month. Most regulatory affairs groups recognize the importance of keeping frequent contact with regulatory agencies, and doing so build better relationships that help drug companies better prepare submission packages for regulatory approval.
Continue Reading here